id	author	title	date	pages	extension	mime	words	sentences	flesch	summary	cache	txt
cord-034406-i1hbx3pz	Matthews, Abigail A.	Developing inhaled protein therapeutics for lung diseases	2020-10-30		.txt	text/plain	8739	395	40	Biologic therapeutics such as protein/polypeptide drugs are conventionally administered systemically via intravenous injection for the treatment of diseases including lung diseases, although this approach leads to low target site accumulation and the potential risk for systemic side effects. In comparison, topical delivery of protein drugs to the lung via inhalation is deemed to be a more effective approach for lung diseases, as proteins would directly reach the target in the lung while exhibiting poor diffusion into the systemic circulation, leading to higher lung drug retention and efficacy while minimising toxicity to other organs. This means that high concentrations of the protein drug can be attained in the lung via pulmonary delivery, suggesting that lower doses of inhaled protein can have an equivalent or even superior therapeutic effect for lung diseases when compared to the higher doses that would be needed from systemic administration [9] .	./cache/cord-034406-i1hbx3pz.txt	./txt/cord-034406-i1hbx3pz.txt